Daré Bioscience, Inc.
San Diego, California, United States · Biotechnology, Biotechnology Research, Healthcare
Daré Bioscience® (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. With eight potentially first-in-class women’s health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate a better quality of life for women.
Key facts
- Headquarters
- San Diego, California, United States
- Employees
- 28
- Industries
- Biotechnology, Biotechnology Research, Healthcare
- Status
- Public (DARE)
- Website
- www.darebioscience.com
- Company page
Recent activity at Daré Bioscience, Inc.
- : SEC 8-K (7.01): On October 1, 2026, Daré Bioscience, Inc. issued a Regulation FD Disclosure regarding a corporate presentation intended for use in meetings with securities market participants. The presentation, dated the same day, outlines key information about the Company's operations and strategic direction. It will be made available on their investor website, enhancing communication with stakeholders and potentially impacting investor perceptions and decisions. The event signifies the Company's engagement strategy aimed at boosting visibility and relationships with the investment community.
- : SEC 8-K (5.03): On September 10, 2026, Daré Bioscience, Inc. approved an amendment to its Third Amended and Restated By-Laws to reduce the quorum requirement for stockholder meetings from a majority to one-third of the voting power of shares entitled to vote. This change aims to facilitate decision-making by lowering the threshold for holding meetings, potentially allowing for more efficient corporate governance. The amendment became effective immediately upon approval by the board of directors.
- : SEC 8-K (7.01): Daré Bioscience, Inc. has furnished a Regulation FD Disclosure under Item 7.01, featuring a corporate presentation dated September 9, 2026. This presentation will be utilized in meetings with securities market participants beginning on the same day. The presentation will also be made available in the Investors section of the Company’s website, enhancing investor engagement and communication regarding corporate strategy. The intention behind this disclosure is to provide transparency and keep stakeholders informed of the Company’s activities and financial positioning.
- : SEC 8-K (1.01): On August 14, 2026, Daré Bioscience, Inc. entered into a securities purchase agreement with institutional investors for the sale of 4,085,687 shares of common stock at an offering price of $1.37 per share, along with pre-funded warrants and common warrants. The pre-funded warrants are immediately exercisable at a price of $0.0001 per share, and the common warrants will only be exercisable upon stockholder approval from Nasdaq, with expirations of five years for Series A Warrants and two years for Series B Warrants. The investors also receive rights for potential cash redemption of warrants under defined fundamental transactions. This agreement is expected to provide Daré with significant capital for operational growth, given the structural rights and adjustments included in the terms of the agreement.
- : Daré Bioscience secures $6.0 million through a registered direct offering and concurrent private placement, led by institutional investors, to advance women's health solutions.
- : SEC 8-K (7.01): On July 24, 2026, Daré Bioscience, Inc. provided a Regulation FD Disclosure regarding a corporate presentation that outlines the company's strategies and projects. This presentation will be utilized in upcoming meetings with securities market participants and will be made available on their website under the 'Investors' section. The content covers significant upcoming events and developments relevant to investors, although specific financial implications were not detailed in this disclosure. This proactive communication is aimed at maintaining transparency with stakeholders and ensuring they are informed of the company's direction.
- : SEC 8-K (7.01): Daré Bioscience, Inc. has furnished a Regulation FD Disclosure through this current report, featuring a corporate presentation dated July 13, 2026. The presentation is intended for use in meetings with securities market participants starting on the same date. It will also be made available on the Company's website under the 'Investors' section. This disclosure relates to the Company's communication strategies aimed at investors and analysts and does not entail any formal filing obligations under the Securities Exchange Act.
- : SEC 8-K (7.01): This filing pertains to Item 7.01, Regulation FD Disclosure, wherein Daré Bioscience, Inc. provided a corporate presentation dated June 22, 2026. The presentation will be utilized in meetings with securities market participants starting on the same date, emphasizing the company's ongoing communication with investors. Daré plans to make this presentation available in the 'Investors' section of its website, which may significantly inform stakeholders about its strategic direction and upcoming initiatives. The importance of this dissemination lies in ensuring transparency and enhancing investor relations as the company seeks to engage effectively with the market.
- : SEC 8-K (5.02): At the annual meeting of stockholders on June 11, 2026, Daré Bioscience, Inc. reported an amendment to their 2022 Stock Incentive Plan, which allows for an increase of 1,500,000 shares available for issuance. The board of directors had previously approved this amendment, contingent upon stockholder approval, which was successfully achieved during the meeting. The voting results confirmed the election of directors for Class III positions and ratified the appointment of Haskell & White LLP as the independent registered public accounting firm for the fiscal year 2026. This amendment and the related approvals are strategic moves to enhance the company's compensation framework and governance structure.
- : SEC 8-K (7.01): On April 22, 2026, Daré Bioscience, Inc. made available an updated corporate presentation in the 'Investors' section of its website. The presentation, dated the same day, provides insights into the company's recent developments and strategic direction. The information is categorized under Regulation FD Disclosure, emphasizing that it is not filed but furnished. This update may impact investor perception and engagement by providing current insights into the company's operations and future plans.
Daré Bioscience, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| Aug 2026 | Post-IPO Equity | $6.0M |
| Dec 2023 | Seed | $1.7M |
| Dec 2023 | Venture | $12.0M |
| Jul 2017 | Venture | $20.7M |
| Oct 2016 | Venture | $1 |
Leadership
- Sabrina, President and CEO
- Sabrina Johnson, Executive Officer, Director
- Jessica Grossman, Director
- Susan Kelley, Director
- Gregory Matz, Director
- William Rastetter, Director
- Robin Steele, Director
- Cheryl Blanchard, Director
- Roger Hawley, Director
Verified email and direct lines for Daré Bioscience, Inc.’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Daré Bioscience, Inc. in the news
- Dare Bioscience Announces New U.S. Patent Strengthening - GlobeNewswire (Sep 28, 2026)
- Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies - Yahoo Finance (May 18, 2026)
- DARÉ Bioscience CEO Sabrina Martucci Johnson Named to Forbes 2026 “50 Over 50: Innovation” List - GlobeNewswire (Aug 18, 2026)
- Daré Bioscience Addresses New National Focus on Women’s Health in Virtual Investor “What This Means” Discussion - GlobeNewswire (Oct 28, 2026)
- Bayer and Daré Bioscience Announce Exclusive Licensing Agreement for U.S. Commercial Rights to Ovaprene - Business Wire (Jan 13, 2020)
- Daré Bioscience Launches “CEO Corner” Video Series to - GlobeNewswire (Oct 13, 2026)
- Daré Bioscience Sponsors HERmedicine Educational Program - GlobeNewswire (Oct 19, 2026)
- Daré Bioscience and Theramex Announce Co-Development and - GlobeNewswire (Feb 20, 2025)
Companies similar to Daré Bioscience, Inc.
- Tenon Medical · Biotechnology, Healthcare, Health Care
- BioLineRx Ltd · Biotechnology, Healthcare, Health Care
- BioCardia · Biotechnology, Healthcare, Health Care
- Procyrion · Biotechnology, Healthcare, Health Care
- Zenflow · Biotechnology, Healthcare, Health Care
About Daré Bioscience, Inc.: questions and answers
What does Daré Bioscience, Inc. do?
Daré Bioscience® (NASDAQ: DARE) is a clinical-stage biopharmaceutical company committed to the advancement of innovative products for women's health. With eight potentially first-in-class women’s health products in development, we are committed to bring to market differentiated products designed to expand treatment options, improve outcomes, and facilitate a better quality of life for women.
Where is Daré Bioscience, Inc. headquartered?
Daré Bioscience, Inc. is headquartered in San Diego, California, United States.
How many employees does Daré Bioscience, Inc. have?
Daré Bioscience, Inc. has about 28 employees.
Has Daré Bioscience, Inc. raised funding?
Yes. Fundz has recorded 5 funding events for Daré Bioscience, Inc.. The most recent, Post-IPO Equity of $6.0M, was in Aug 2026.
Who leads Daré Bioscience, Inc.?
Sabrina is a President and CEO at Daré Bioscience, Inc..
What is the latest news on Daré Bioscience, Inc.?
On Oct 01, 2026, SEC 8-K (7.01): On October 1, 2026, Daré Bioscience, Inc. issued a Regulation FD Disclosure regarding a corporate presentation intended for use in meetings with securities market participants. The presentation, dated the same day, outlines key information about the Company's operations and strategic
Is Daré Bioscience, Inc. a public company?
Yes. Daré Bioscience, Inc. is publicly traded under the ticker DARE.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy